Endpoints News 9 avr. 2026 Roche dips into DACs with existing partner C4 Therapeutics for $20M upfront
Endpoints News 20 mars 2026 Genentech culls muscle-preserving drug in genetic diseases, raising questions about obesity trial
Endpoints News 9 févr. 2026 #ACTRIMS26: Roche’s MS drug fenebrutinib beats Ocrevus, cutting risk of disability progression by 12%
Endpoints News 8 janv. 2026 Ollin’s drug clears retinal disease better than Roche’s Vabysmo in Phase 1b trial
Endpoints News 8 janv. 2026 Charles Fuchs leaves Roche to steer ADC pipeline at Tubulis shortly after $401M Series C
Endpoints News 8 janv. 2026 Former Genentech leaders’ protein degrader startup EpiBiologics nets $107M
Endpoints News 10 déc. 2025 #SABCS25: Roche’s breast cancer pill cuts post-surgery disease recurrence risk by 30%
Endpoints News 4 déc. 2025 Clinical trials tech startup Paradigm raises $78M, acquires part of Roche’s Flatiron